Researchers identify new marker for breast cancer prognosis

A protein called retinitis pigmentosa GTPase regulator interacting protein 1-like (RPGRIP1L) performs various functions that are important for development and for health throughout life, and mutations in the RPGRIP1L gene have been linked to different diseases. New research published in The FASEB Journal indicates that expression levels of the RPGRIP1L gene might serve as a new prognostic marker for individuals with invasive breast cancer.

When investigators examined breast tissue specimens from different women, they found that the expression of RPGRIP1L was elevated in invasive breast cancer specimens compared with normal breast tissue specimens. Also, among patients with invasive breast cancer, those with higher RPGRIP1L gene expression had shorter survival times than those with low expression. Furthermore, elevated expression of RPGRIP1L corresponded with a spectrum of unfavorable clinicopathological features such as the presence of more aggressive forms of cancer and larger tumors.

The researchers also identified 50 genes and 15 proteins whose expression was positively related to RPGRIP1L expression, with most of these proteins and genes being involved in different aspects of the immune response and metabolism.

Finally, the team found that 4 compounds used against cancer—abrine, epigallocatechin gallate, gentamicin, and tretinoin—showed potential for reducing the expression of RPGRIP1L in lab experiments.

“The findings of our research underscore the potential of RPGRIP1L as a significant prognostic biomarker for breast cancer and suggest the viability of novel therapeutic strategies that may modify disease progression, thus potentially enhancing survival rates among affected individuals,” said co–corresponding author Jie Zeng, PhD, of the First Affiliated Hospital of Hunan Normal University, in China.

URL upon publication:

Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.

About the Journal
The FASEB Journal publishes multidisciplinary research covering biology and biomedical sciences at every level of organization: atomic, molecular, cell, tissue, organ, organismic, and population. The journal’s scope includes the spectrum of biological and biomedical sciences as well as interdisciplinary research cutting across multiple fields and extending into related areas.

About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world’s most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.